Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Stephan Petersenn · Andrew J. Farrall · Christophe De Block · Shlomo Melmed ·
Jochen Schopohl · Philippe Caron · Ross Cuneo · David Kleinberg ·
Annamaria Colao · Matthieu Ruffin · Karina Hermosillo Reséndiz ·
Gareth Hughes · Ke Hu · Ariel Barkan

Published online: 30 May 2013
© Springer Science+Business Media New York 2013

Erratum to: Pituitary DOI 10.1007/s11102-013-0478-0

The surname of one of the authors, Christophe De Block, has been spelt incorrectly as Block instead of De Block.

The online version of the original article can be found under doi:[10.1007/s11102-013-0478-0](https://doi.org/10.1007/s11102-013-0478-0).

S. Petersenn (✉)
ENDOC Center for Endocrine Tumors, Altonaer Str. 59,
20357 Hamburg, Germany
e-mail: stephan.petersenn@endoc-med.de

A. J. Farrall
Brain Research Imaging Centre, Western General Hospital,
University of Edinburgh, Edinburgh, UK

C. De Block
Department of Endocrinology, Diabetology and Metabolism,
Antwerp University Hospital, Antwerp, Belgium

S. Melmed
Division of Endocrinology and Metabolism, Cedars-Sinai
Medical Center, Los Angeles, CA, USA

J. Schopohl
Medizinische Klinik und Poliklinik IV, Campus Innenstadt,
University of Munich, Munich, Germany

P. Caron
Service d'Endocrinologie, Maladies Métaboliques et Nutrition,
Centre Hospitalier Universitaire Larrey, Toulouse, France

R. Cuneo
Department of Diabetes and Endocrinology, Princess Alexandra
Hospital, Brisbane, Australia

D. Kleinberg
Neuroendocrine Unit, New York University School of Medicine,
New York, NY, USA

A. Colao
Dipartimento di Medicina Clinica e Chirurgia, Università
Federico II di Napoli, Naples, Italy

M. Ruffin · G. Hughes
Novartis Pharma AG, Basel, Switzerland

K. Hermosillo Reséndiz · K. Hu
Novartis Pharmaceuticals, East Hanover, NJ, USA

A. Barkan
Pituitary and Neuroendocrine Center, University of Michigan,
Ann Arbor, MI, USA